No Data
Express News | Larimar Therapeutics Shares Hit Session Low With Volume Pickup, Last Down 5.3% at $6.04
Larimar Therapeutics Presents Additional Data From Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024
Is Larimar Therapeutics (LRMR) the Best Multibagger Stock to Buy Heading Into 2025?
Watching Larimar Therapeutics; Traders Circulate Stock Picked By Zacks Under $10 Newsletter
Oppenheimer Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $26
Express News | Larimar Therapeutics Inc : Guggenheim Raises Target Price to $26 From $25
No Data